Department of Computer Engineering, Sharif University of Technology, Tehran, Iran.
BMC Genomics. 2024 May 9;25(1):411. doi: 10.1186/s12864-024-10326-x.
In recent years, there has been a growing interest in utilizing computational approaches to predict drug-target binding affinity, aiming to expedite the early drug discovery process. To address the limitations of experimental methods, such as cost and time, several machine learning-based techniques have been developed. However, these methods encounter certain challenges, including the limited availability of training data, reliance on human intervention for feature selection and engineering, and a lack of validation approaches for robust evaluation in real-life applications.
To mitigate these limitations, in this study, we propose a method for drug-target binding affinity prediction based on deep convolutional generative adversarial networks. Additionally, we conducted a series of validation experiments and implemented adversarial control experiments using straw models. These experiments serve to demonstrate the robustness and efficacy of our predictive models. We conducted a comprehensive evaluation of our method by comparing it to baselines and state-of-the-art methods. Two recently updated datasets, namely the BindingDB and PDBBind, were used for this purpose. Our findings indicate that our method outperforms the alternative methods in terms of three performance measures when using warm-start data splitting settings. Moreover, when considering physiochemical-based cold-start data splitting settings, our method demonstrates superior predictive performance, particularly in terms of the concordance index.
The results of our study affirm the practical value of our method and its superiority over alternative approaches in predicting drug-target binding affinity across multiple validation sets. This highlights the potential of our approach in accelerating drug repurposing efforts, facilitating novel drug discovery, and ultimately enhancing disease treatment. The data and source code for this study were deposited in the GitHub repository, https://github.com/mojtabaze7/DCGAN-DTA . Furthermore, the web server for our method is accessible at https://dcgan.shinyapps.io/bindingaffinity/ .
近年来,利用计算方法预测药物-靶标结合亲和力的兴趣日益浓厚,旨在加速早期药物发现过程。为了解决实验方法的局限性,如成本和时间,已经开发了几种基于机器学习的技术。然而,这些方法存在一些挑战,包括训练数据的有限可用性、对人工干预的特征选择和工程的依赖,以及缺乏稳健评估的验证方法,以适用于实际应用。
为了缓解这些限制,在本研究中,我们提出了一种基于深度卷积生成对抗网络的药物-靶标结合亲和力预测方法。此外,我们进行了一系列验证实验,并使用 straw 模型进行了对抗控制实验。这些实验证明了我们的预测模型的稳健性和有效性。我们通过将我们的方法与基线和最先进的方法进行比较,对我们的方法进行了全面评估。为此,我们使用了两个最近更新的数据集,即 BindingDB 和 PDBBind。我们的研究结果表明,在使用热身数据拆分设置时,我们的方法在三个性能指标上优于替代方法。此外,在考虑基于物理化学的冷启动数据拆分设置时,我们的方法表现出优越的预测性能,特别是在一致性指数方面。
我们的研究结果证实了我们的方法的实用价值及其在多个验证集中预测药物-靶标结合亲和力方面的优越性。这突出了我们的方法在加速药物再利用、促进新药发现和最终增强疾病治疗方面的潜力。本研究的数据和源代码存储在 GitHub 存储库中,网址为 https://github.com/mojtabaze7/DCGAN-DTA。此外,我们方法的网络服务器可在 https://dcgan.shinyapps.io/bindingaffinity/ 访问。